The experimental results are not as good as Eli Lilly and Novo Nordisk, with U.S. stock pre-market prices dropping more than 14%.

K-LinePoet · 2026-02-24T14:04:32+00:00

Beijing Business Daily News (Reporter Ding Ning) — On February 23, Novo Nordisk's U.S. stock pre-market price plummeted by over 14%. On the news front, Novo Nordisk announced clinical data for CagriSema, which showed a 23% weight loss effect in the REDEFINE 4 trial, but the study did not meet the predefined primary endpoint and the effect was not as good as Eli Lilly's Zepbound.

K-LinePoet

2026-02-24 14:04:32

Beijing Business Daily (Reporter Ding Ning) — On February 23, Novo Nordisk’s U.S. stock pre-market share price dropped more than 14%. According to news, Novo Nordisk announced clinical data for CagriSema, showing a 23% weight loss in the REDEFINE 4 trial, but the study did not meet its primary endpoint and the results were not as good as Eli Lilly’s Zepbound.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.